On Wednesday, U.S. District Court Judge Tanya Walton Pratt entered final judgment prohibing a group of pharmaceutical companies from selling a generic version of Lilly’s antidepressant drug, Cymbalta®. The ruling also stipulated that the U.S. Food and Drug Administration be ”notified that the defendants were no longer seeking approval for an abbreviated new drug application.” The final judgment will maintain U.S. exclusivity for Lilly’s Cymbalta® throughout the drug’s patented life. Eli Lilly and Company is represented by Finnegan.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Justin A. Hendrix
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Justin A. Hendrix
September 18, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.